Boston Scientific

BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent  

Retrieved on: 
Freitag, Mai 3, 2024
Science, Sorin Group, Rowan University, University, GXP, Organization, Pharmacy, Blood, Laboratory, Safety, Hospital, Supreme court, Whittier Law School, University of Pittsburgh, Bankruptcy, Johnson & Johnson, Business administration, United States district court, Supreme, MLAB, District court, Biosensors International, Wilfrid Laurier University, UCC, La Salle College, Brownstein Hyatt Farber Schreck, St. Jude Medical, University of Chicago, Boston Scientific, Management

The final compositions of the committees to the Board will be determined in the very near term.

Key Points: 
  • The final compositions of the committees to the Board will be determined in the very near term.
  • The Board is now compliant with the rules and regulations that govern the standards acceptable to major U.S.
  • Mr. Amato has hands-on executive skills at engaging and influencing key stakeholders to not only grow business but also to optimize profits.
  • Mr. Amato founded InQuest Science in March 2017 and then acquired Bridge Associates International Pharmaceutical Consulting in March 2020.

Inclusive Workforce Pathways Emerge as the Cornerstone for Corporate Resilience

Retrieved on: 
Donnerstag, Mai 2, 2024
Education, Salesforce, Organization, The Coca-Cola Company, Equity, Viad, Walt Disney, IDEA, Woman, Korn Ferry, AI, Cigna, Kohl's, Warner Bros. Discovery, Partnership, Life, Spelman, Culture, Novartis, Bristol Myers Squibb, Zurich Insurance Group, Booz Allen Hamilton, LHH, Noise, AIG, Workforce, CDW, Digimarc, Student, Spelman College, Boston Scientific, Management

WASHINGTON, May 2, 2024 /PRNewswire/ --  Tapestry Networks' Inclusion, Diversity, and Equity in Action (IDEA) initiative, in partnership with Spelman College, a global leader in the education of women of African descent, will host Reimagining the Future of Talent, a dialogue on the convergence of talent, technology, corporate culture, and workforce equity as mobilizers of business strategy. Given profound differences between Fortune 100 directors and students entering the workforce, and rapidly changing employer-employee relationships, this forum arrives at a critical juncture as boards seek to respond to global forces shaping the future of work, and to create inclusive talent pathways in their companies.

Key Points: 
  • Talent can make or break a company, especially in uncertain times.
  • "Talent can make or break a company, especially in uncertain times," said Dr. Marsha H. Ershaghi, Managing Director, Tapestry Networks.
  • Directors want to push the pace of progress and want to get to know the priorities of the newest generations in the workforce."
  • Reimagining the Future of Talent will take place September 19, 2024, on Spelman College's Atlanta campus.

Cardiac Monitoring & Cardiac Rhythm Management Devices Market Worth $26.4 billion | MarketsandMarkets™

Retrieved on: 
Donnerstag, Mai 2, 2024
USD, MicroPort, FDA, Asahi Kasei, Investment, GE HealthCare, Laboratory, Risk, Hospital, Monitor lizard, Biomedical Research, Research, ECG, Abbott Laboratories, Baxter International, ICM, Patient, Boston Scientific, Acquisition, Arrhythmia, Cardiology, Diagnosis, Biotechnology, Market development, Medical device

Based on the North America region, the cardiac monitoring & cardiac rhythm management devices Market is divided into US and Canada.

Key Points: 
  • Based on the North America region, the cardiac monitoring & cardiac rhythm management devices Market is divided into US and Canada.
  • Cardiac Monitoring & Cardiac Rhythm Management Devices Market Dynamics:
    Key Market Players of Cardiac Monitoring & Cardiac Rhythm Management Devices Industry:
    The major players in the cardiac monitoring & cardiac rhythm management devices Market are Abbott Laboratories (US), Medtronic (Ireland), Boston Scientific Corporation (US), GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), Asahi Kasei Corporation.
  • {deal size USD 12.5 billion}
    Cardiac Monitoring & Cardiac Rhythm Management Devices Market - Key Benefits of Buying the Report:
    This report studies the cardiac monitoring & cardiac rhythm management devices market based on Type, Application, Procedure, End User, and Region.
  • Market Penetration: Comprehensive information on cardiac monitoring & cardiac rhythm management devices Market products offered by the top 25 players in the market.

Cardiac Monitoring & Cardiac Rhythm Management Devices Market Worth $26.4 billion | MarketsandMarkets™

Retrieved on: 
Donnerstag, Mai 2, 2024
USD, MicroPort, FDA, Asahi Kasei, Investment, GE HealthCare, Laboratory, Risk, Hospital, Monitor lizard, Biomedical Research, Research, ECG, Abbott Laboratories, Baxter International, ICM, Patient, Boston Scientific, Acquisition, Arrhythmia, Cardiology, Diagnosis, Biotechnology, Market development, Medical device

Based on the North America region, the cardiac monitoring & cardiac rhythm management devices Market is divided into US and Canada.

Key Points: 
  • Based on the North America region, the cardiac monitoring & cardiac rhythm management devices Market is divided into US and Canada.
  • Cardiac Monitoring & Cardiac Rhythm Management Devices Market Dynamics:
    Key Market Players of Cardiac Monitoring & Cardiac Rhythm Management Devices Industry:
    The major players in the cardiac monitoring & cardiac rhythm management devices Market are Abbott Laboratories (US), Medtronic (Ireland), Boston Scientific Corporation (US), GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), Asahi Kasei Corporation.
  • {deal size USD 12.5 billion}
    Cardiac Monitoring & Cardiac Rhythm Management Devices Market - Key Benefits of Buying the Report:
    This report studies the cardiac monitoring & cardiac rhythm management devices market based on Type, Application, Procedure, End User, and Region.
  • Market Penetration: Comprehensive information on cardiac monitoring & cardiac rhythm management devices Market products offered by the top 25 players in the market.

Boston Scientific Announces Upcoming Investor Conference Schedule

Retrieved on: 
Mittwoch, Mai 1, 2024
Boston Scientific, BSX, Bank, Conference

MARLBOROUGH, Mass., May 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.

Key Points: 
  • MARLBOROUGH, Mass., May 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.
  • The session will begin at approximately 8:40 a.m. PT / 11:40 a.m.
  • On May 29, 2024, Mike Mahoney, chairman and chief executive officer, will participate in a 50-minute question-and-answer session with the host analyst at Bernstein's 40th Annual Strategic Decisions Conference.
  • The replay will be available approximately one hour following the completion of the event.

USPAACC Announces CelebrASIAN 2024 Procurement + Business Conference, May 29-31, The Hotel at Avalon, Autograph Collection, Alpharetta, Ga.

Retrieved on: 
Montag, April 29, 2024
MSD, DEI, MassMutual, RTX, City, Wells Fargo, AT&T, Woman, International finance, Fannie Mae, Conference, Supplier diversity, USDA, Transport, Inclusion, SAS Institute, Cushman & Wakefield, Senior, JPMorgan Chase, Access, Commerce, Representation, Communication, Marketing, FDIC, Hotel, Government, T-Mobile, Boston Scientific, COVID-19, Penn Entertainment, Management

For over 39 years, CelebrASIAN has launched successful business partnerships among Fortune 1000 corporations, federal agencies, nonprofits, and diverse enterprises.

Key Points: 
  • For over 39 years, CelebrASIAN has launched successful business partnerships among Fortune 1000 corporations, federal agencies, nonprofits, and diverse enterprises.
  • CelebrASIAN features A-list speakers from Fortune 1000 Corporations, high-level government officials, and rising stars of the Pan Asian American and diverse business communities.
  • CelebrASIAN brings together top-caliber participants from the business, nonprofit, and government sectors all under one roof," said USPAACC CEO Susan Au Allen.
  • Email [email protected] for more information about CelebrASIAN, May 29-31, The Hotel at Avalon, Autograph Collection, Alpharetta, Ga.

Affluent Medical : 2023 financial results and update on clinical activities under development.

Retrieved on: 
Freitag, Mai 3, 2024
Medtech, FDA, Risk, De novo, Death, Mitral regurgitation, Doctor of Philosophy, Wound healing, Mitral valve annuloplasty, Boston Scientific, Ticker, Wealth, Urinary incontinence, Woman, Christophe, Food, Neurostimulation, Myocardial infarction, Aix-en-Provence, DSM-IV codes, LCEA, Mitral valve, TAVI, Minerva, Certification, Heart, Quality assurance, System, Anatomy, Exercise, NYHA, Dry, Marketing, Clinical trial, American College, Development director, MD, Endocarditis, Medtronic, Patient, Tricuspid valve, Acquisition, Medical device

Affluent Medical : 2023 financial results and update on clinical activities under development.

Key Points: 
  • Affluent Medical : 2023 financial results and update on clinical activities under development.
  • Affluent Medical estimates that KaliosTM would avoid repeat surgery for 30-40% of patients within five years of their operation.
  • In September 2023, the Company presented interim data on 20 patients treated in five clinical centers in Europe after one year of implantation.
  • In July 2023, Affluent Medical announced the appointments of Christophe de Vregille as Chief Financial Officer and Benjamin Renault as Development Director.

Axonics Reports First Quarter 2024 Financial Results

Retrieved on: 
Dienstag, April 30, 2024
Medical Supplies, Medical Devices, Health, Neurology, Health Technology, Biotechnology, Acquisition, Patient, Investment, Incontinence, Boston Scientific, Pharmaceutical industry

Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024.
  • “Our growth was driven by higher utilization and share of wallet for existing sacral neuromodulation customers and the onboarding of new accounts.
  • Due to the pending merger with Boston Scientific, Axonics stopped issuing new equity grants to employees as of January 2024.
  • Cash, cash equivalents, short-term investments and restricted cash were $349 million as of March 31, 2024.

Medicines360 Appoints Erica Rogers to Board of Directors

Retrieved on: 
Mittwoch, April 10, 2024
Medtech, Organon, Woman, Engineering, IPO, Science, Boston Scientific, SAN, Pharmaceutical industry

SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Medicines360, a global mission-driven women's health company that focuses on developing new products and accelerating access to innovation for women, has appointed Erica Rogers to the Board of Directors, effective March 8, 2024.

Key Points: 
  • SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Medicines360, a global mission-driven women's health company that focuses on developing new products and accelerating access to innovation for women, has appointed Erica Rogers to the Board of Directors, effective March 8, 2024.
  • Ms. Rogers, an accomplished innovator and entrepreneur, brings over 30 years of experience leading high-growth health technology companies to Medicines360.
  • “Medicines360 has demonstrated considerable impact, helping over 1.5 million women to date, driven by its mission to improve equitable health outcomes,” said Ms. Rogers.
  • “We are thrilled to welcome Erica Rogers to our Board of Directors.

Volato Announces Changes to Board Composition

Retrieved on: 
Mittwoch, April 24, 2024
Other Travel, Fleet Management, Transportation, Travel, Automotive, Other Transport, Air, Transport, University, Motorola, Electricity, Annual report, Transform, Biomedical engineering, Business administration, Compensated emancipation, Webcast, Intelligence, Biomedicine, Delta Air Lines, Audit committee, Access, Acquisition, Lead, FedEx, Boston Scientific, BSX, Aviation, Specialization, Interest, Management

Volato Group, Inc. (“Volato,” or the “Company”) (NYSE American: SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company’s Board of Directors.

Key Points: 
  • Volato Group, Inc. (“Volato,” or the “Company”) (NYSE American: SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company’s Board of Directors.
  • The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors.
  • Matthew Liotta, Chief Executive Officer and Co-Founder of Volato, has been elected Chairman of the Board of Directors.
  • Mr. Colen is qualified to serve on the Board because of his significant public company board and managerial experience.